Aeterna Zentaris - AEZS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.50
  • Forecasted Upside: 871.50 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.86
▼ -0.01 (-0.26%)

This chart shows the closing price for AEZS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aeterna Zentaris Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AEZS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AEZS

Analyst Price Target is $37.50
▲ +871.50% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Aeterna Zentaris in the last 3 months. The average price target is $37.50, with a high forecast of $37.50 and a low forecast of $37.50. The average price target represents a 871.50% upside from the last price of $3.86.

This chart shows the closing price for AEZS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Aeterna Zentaris.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/14/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/6/2022HC WainwrightDowngradeBuy ➝ NeutralLow
3/30/2022HC WainwrightLower TargetBuy$50.00 ➝ $37.50Low
10/25/2021HC WainwrightReiterated RatingBuyHigh
8/15/2019HC WainwrightReiterated RatingBuyLow
1/17/2019HC WainwrightReiterated RatingBuyLow
12/20/2018Maxim GroupSet TargetBuy$50.00Low
12/20/2018HC WainwrightSet TargetBuy$75.00Low
11/14/2018HC WainwrightReiterated RatingBuy$75.00Low
6/15/2018Maxim GroupReiterated RatingBuyLow
5/9/2018HC WainwrightReiterated RatingBuy$75.00High
3/29/2018HC WainwrightReiterated RatingBuy$75.00Low
3/28/2018Maxim GroupSet TargetBuy$100.00Medium
1/17/2018Maxim GroupSet TargetBuy$100.00High
12/21/2017Maxim GroupSet TargetBuy$100.00High
(Data available from 12/10/2017 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/13/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Aeterna Zentaris logo
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Read More

Today's Range

Now: $3.86
Low: $3.75
High: $4.00

50 Day Range

MA: $3.82
Low: $3.57
High: $4.34

52 Week Range

Now: $3.86
Low: $3.51
High: $11.60

Volume

38,789 shs

Average Volume

38,151 shs

Market Capitalization

$18.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Aeterna Zentaris?

The following Wall Street analysts have issued stock ratings on Aeterna Zentaris in the last year: HC Wainwright, and StockNews.com.
View the latest analyst ratings for AEZS.

What is the current price target for Aeterna Zentaris?

1 Wall Street analysts have set twelve-month price targets for Aeterna Zentaris in the last year. Their average twelve-month price target is $37.50, suggesting a possible upside of 871.5%. HC Wainwright has the highest price target set, predicting AEZS will reach $37.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $37.50 for Aeterna Zentaris in the next year.
View the latest price targets for AEZS.

What is the current consensus analyst rating for Aeterna Zentaris?

Aeterna Zentaris currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AEZS will outperform the market and that investors should add to their positions of Aeterna Zentaris.
View the latest ratings for AEZS.

What other companies compete with Aeterna Zentaris?

How do I contact Aeterna Zentaris' investor relations team?

Aeterna Zentaris' physical mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company's listed phone number is (843) 900-3223 and its investor relations email address is [email protected] The official website for Aeterna Zentaris is www.zentaris.com. Learn More about contacing Aeterna Zentaris investor relations.